{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:40:30Z","timestamp":1767966030090,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jtct.2023.04.005","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T11:44:54Z","timestamp":1681472694000},"page":"459.e1-459.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms"],"prefix":"10.1016","volume":"29","author":[{"given":"Christian J.","family":"Puzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Tormey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry M.","family":"Rinder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2372-3653","authenticated-orcid":false,"given":"Alexa J.","family":"Siddon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.04.005_bib0001","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00129785-200404030-00005","article-title":"Diagnostic chimerism analysis after allogeneic stem cell transplantation","volume":"4","author":"Thiede","year":"2004","journal-title":"Am J Pharmacogenomics"},{"key":"10.1016\/j.jtct.2023.04.005_bib0002","article-title":"Donor chimerism of B cells and nature killer cells provides useful information to predict hematologic relapse following allogeneic hematopoietic stem cell transplantation","volume":"10","author":"Jiang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtct.2023.04.005_bib0003","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/bmt.2014.158","article-title":"Quantitative chimerism: an independent acute leukemia prognosis indicator following allogeneic hematopoietic SCT","volume":"49","author":"Qin","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.005_bib0004","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.bbmt.2014.07.003","article-title":"Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning","volume":"20","author":"Reshef","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.005_bib0005","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood.2019004770","article-title":"Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia","volume":"135","author":"Hasserjian","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.04.005_bib0006","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2018-04-848028","article-title":"Next-generation sequencing\u2013based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse","volume":"132","author":"Kim","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.04.005_bib0007","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-021-00500-9","article-title":"Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia","volume":"11","author":"Kim","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2023.04.005_bib0008","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","article-title":"Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations","volume":"5","author":"Heuser","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.04.005_bib0009","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.3390\/jcm9123818","article-title":"Assessment of minimal residual disease by next generation sequencing in peripheral blood as a complementary tool for personalized transplant monitoring in myeloid neoplasms","volume":"9","author":"Aguirre-Ruiz","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtct.2023.04.005_bib0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fcell.2020.00249","article-title":"Sequencing-based measurable residual disease testing in acute myeloid leukemia","volume":"8","author":"Yoest","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jtct.2023.04.005_bib0011","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1080\/10428194.2020.1759051","article-title":"Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience","volume":"61","author":"Bewersdorf","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2023.04.005_bib0012","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.pathol.2021.01.005","article-title":"Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome","volume":"53","author":"Hughes","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.jtct.2023.04.005_bib0013","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fonc.2017.00206","article-title":"Familial myelodysplastic\/acute leukemia syndromes-myeloid neoplasms with germline predisposition","volume":"7","author":"Baptista","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2023.04.005_bib0014","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood.2019003079","article-title":"Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation","volume":"135","author":"Boettcher","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.04.005_bib0015","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/MOH.0000000000000631","article-title":"Clonal hematopoiesis in hematopoietic stem cell transplantation","volume":"28","author":"Wilk","year":"2021","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jtct.2023.04.005_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224097","article-title":"Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing","volume":"14","author":"Balagopal","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jtct.2023.04.005_bib0017","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11899-018-0479-1","article-title":"Minimal\/measurable residual disease detection in acute leukemias by multiparameter flow cytometry","volume":"13","author":"Fuda","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.jtct.2023.04.005_bib0018","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s00277-019-03782-z","article-title":"Clinician-friendly reports of molecular measurable residual disease monitoring in acute promyelocytic leukemia","volume":"98","author":"Wu","year":"2019","journal-title":"Ann Hematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672301237X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672301237X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:10:46Z","timestamp":1763003446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672301237X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S266663672301237X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.04.005","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}